Laboratoires Servier

Servier Laboratories (French: Laboratoires Servier, often abbreviated to Servier) is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Suresnes).[3]

This article is about the pharmaceutical company. For other uses, see Servier (disambiguation).
Servier
Private
IndustryPharmaceutical
Founded(1954 (1954))
FounderJacques Servier
Headquarters
Suresnes
,
France
ProductsPharmaceuticals
Revenue€4.2 billion (FY 2018)
Number of employees
22,000
WebsiteOfficial website
Footnotes / references
[1][2]

The consolidated turnover for the 2018 financial year was €4.2 billion.[4] Servier is the leading French independent pharmaceutical company, and the second largest French pharmaceutical company worldwide. It has branches in 149 countries, achieving 82% of its sales outside France.[5][6] The company reportedly invests a little under 25% of its turnover in research and development, which occupies 3,000 of its 22,000 employees worldwide.[7] The company's production sites produced 853 million drug boxes in 2013.[5]

The Servier Clinical Support Unit in Gidy (near Orléans), which produces drugs for clinical trials, is the largest unit of its kind in Europe.[8] Servier Laboratories is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA).[9]

In 2018, Servier finalized the acquisition of Shire’s oncology branch in Boston. The official opening of Servier's new U.S. headquarters took place in 2019.[4]

Mediator, an amphetamine-based Servier drug originally developed for weight loss in people with diabetes but often prescribed off-label as a dieting aid, was withdrawn from the market after being linked to 500–2000 deaths in France.[10][11] Further investigations found that many previous safety alerts on that drug had been either missed or covered up, possibly due to the improper influence of the company.[11]

Product portfolio

Notable products:

Other products:

Collaborative research

As well as internal research and development activities, Servier undertakes publicly funded collaborative research projects with industrial and academic partners. One example, in the area of non-clinical safety assessment, is the InnoMed PredTox.[14][15] The company is expanding its activities in joint research projects within the framework of the Innovative Medicines Initiative of EFPIA and the European Commission.[16]

In addition to these, Servier engages in research and licensing collaborations across the pharmaceutical and biotechnology industry. These collaborations include:

  • In Cardiology: XENTION (UK, 2013), AMGEN (USA, 2013), MIRAGEN (USA, 2011), ARMGO (USA, 2006)
  • In Diabetes: INTARCIA (USA, 2014)
  • In Metabolic diseases: INTERCEPT - TGR5 agonists (USA, 2011), GENFIT (FR, 2004)
  • In Neurology (MS): GENEURO (CH, 2014)
  • In Oncology: CTI BIOPHARMA (USA, 2014), NOVARTIS (CH, 2014), CELLECTIS (FR, 2014), NERVIANO (IT, 2013), EOS (IT) / CLOVIS (USA, 2012), BIOINVENT (SE, 2012), MACROGENICS (USA, 2011/12), GALAPAGOS (NDL, 2011), BIOREALITES (FR, 2011), PHARMACYCLICS - HDAC inhibitor (USA, 2009), HYBRIGENICS (FR, 2007/2011) VERNALIS (UK, 2007/2011)
  • In Orphan Diseases/Cardiology/Diabetes: XOMA (USA, 2010)
  • In Osteoporosis & Osteoarthritis: OSTEOLOGIX (USA, 2010), GALAPAGOS (NDL, 2010), KAROS (USA, 2010), NORDIC BIOSCIENCE (DK, 2006/2010)

Servier acquired Symphogen in 2020.[17]

Controversy

Servier Laboratories has been the object of worldwide scandal for creating and distributing a weight-loss drug called Mediator, which may have killed up to 2,100 people.[18]

The movie 150 Milligrams, by director Emmanuelle Bercot, features Dr. Irène Frachon discovering that Mediator pills cause heart valve problems/deaths and how in 2009 she starts an uphill battle against the producer and the French health authorities.

gollark: Idea: be really inconsistent about what stuff *actually* costs a lot to make/is important/valuable, to trick people into damaging and stealing random useless stuff!
gollark: Well, the forcefield should get him anyway.
gollark: Uprisings will be removed with laser bees.
gollark: The laser bees sting any hostile mob which spawns, so they don't exist.
gollark: We also used quarries to unexist most nearby ore, and also all caves underneath the test village are lit up now, and also also there are no hostile mobs there.

References
  1. "Key figures". Servier. Retrieved 2015-02-03.
  2. "History". Servier. Retrieved 2015-02-03.
  3. "French drug maker Servier sets up US headquarters in Seaport". Boston Globe. May 9, 2019.
  4. "Servier launches U.S. cancer business with plans to double headcount in next 5 years". Boston Business Journal. May 9, 2019.
  5. "SERVIER - Pharmaceutical company specialized in cardiology, diabetes, rheumatology, depression". Retrieved 2007-07-08.
  6. "Servier and Galapagos complete enrollment of global ROCCELLA Phase 2 clinical trial with GLPG1972/S201086 in knee osteoarthritis". Bloomberg. June 11, 2019.
  7. "Servier's US push takes shape as Boston HQ opens". BioPharma Dive. May 9, 2019.
  8. "Servier UK - Key figures". Archived from the original on 2007-07-08. Retrieved 2007-07-08.
  9. "The Pharmaceutical Industry in Figures - 2008 Edition". European Federation of Pharmaceutical Industries and Associations (EFPIA). p. 49. Archived from the original on 2008-09-16. Retrieved 2008-08-25.
  10. Article of the Figaro about Mediator
  11. Un doute sur la «sécurité» du Mediator dès 1998 - Libération
  12. "SERVIER - product portfolio". Archived from the original on 2007-07-02. Retrieved 2007-07-08.
  13. https://servier.com/wp-content/uploads/2018/08/PR-Servier-Shire-Oncology-Acquisition_2018.08.31.pdf
  14. Mattes, William B. (2008). "Public Consortium Efforts in Toxicogenomics". In Mendrick, Donna L.; Mattes, William B. (eds.). Essential Concepts in Toxicogenomics. Methods in Molecular Biology. 460. pp. 221–238. doi:10.1007/978-1-60327-048-9_11. ISBN 978-1-58829-638-2. PMID 18449490.
  15. "InnoMed PredTox Member Organizations". Archived from the original on 2008-09-26. Retrieved 2008-08-25.
  16. Innovative Medicines Initiative. "IMI Call Topics 2008". IMI-GB-018v2-24042008-CallTopics.pdf. European Commission. Archived from the original on 2009-10-15. Retrieved 2008-08-25.
  17. A/S, Symphogen (3 April 2020). "Servier signed a definitive agreement to acquire Symphogen, a leading antibody discovery company, to boost its antibody capabilities and leverage its R&D pipeline". GlobeNewswire News Room.
  18. Samuel, Henry (2019-09-23). "Trial opens in France over weight loss drug that 'killed hundreds'". The Telegraph. ISSN 0307-1235. Retrieved 2020-04-03.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.